AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response

 
• By Sarah Karlin-Smith
  
Rock climber dangling over edge of mountain trying to get up.
AstraZeneca's Andexxa is the latest product cleared through accelerated approval to remain dangling after failing to convert to full approval. (Shutterstock)

More from Complete Response Letters

More from Regional Comparisons